- Home
- CRDF vs DRTS Comparison
CRDF vs DRTS Comparison
Compare CRDF & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- DRTS
- Stock Information
- Founded
- CRDF 1999
- DRTS 2015
- Country
- CRDF United States
- DRTS Israel
- Employees
- CRDF N/A
- DRTS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- DRTS Medical/Dental Instruments
- Sector
- CRDF Health Care
- DRTS Health Care
- Exchange
- CRDF Nasdaq
- DRTS Nasdaq
- Market Cap
- CRDF 233.5M
- DRTS 256.2M
- IPO Year
- CRDF N/A
- DRTS N/A
- Fundamental
- Price
- CRDF $2.32
- DRTS $3.21
- Analyst Decision
- CRDF Strong Buy
- DRTS Strong Buy
- Analyst Count
- CRDF 6
- DRTS 1
- Target Price
- CRDF $10.58
- DRTS $9.00
- AVG Volume (30 Days)
- CRDF 2.9M
- DRTS 60.6K
- Earning Date
- CRDF 07-29-2025
- DRTS 08-11-2025
- Dividend Yield
- CRDF N/A
- DRTS N/A
- EPS Growth
- CRDF N/A
- DRTS N/A
- EPS
- CRDF N/A
- DRTS N/A
- Revenue
- CRDF $545,000.00
- DRTS N/A
- Revenue This Year
- CRDF N/A
- DRTS N/A
- Revenue Next Year
- CRDF N/A
- DRTS N/A
- P/E Ratio
- CRDF N/A
- DRTS N/A
- Revenue Growth
- CRDF N/A
- DRTS N/A
- 52 Week Low
- CRDF $2.09
- DRTS $2.11
- 52 Week High
- CRDF $5.64
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- CRDF 34.12
- DRTS 52.03
- Support Level
- CRDF $2.22
- DRTS $3.03
- Resistance Level
- CRDF $2.56
- DRTS $3.58
- Average True Range (ATR)
- CRDF 0.13
- DRTS 0.20
- MACD
- CRDF 0.01
- DRTS -0.01
- Stochastic Oscillator
- CRDF 25.64
- DRTS 38.33
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.